Since intra-arterial chemotherapy for retinoblastoma reemerged five years ago, the procedure has been performed successfully in more than 25 countries, with high rates of globe salvage. But as the procedure has gained traction, significant complications and unanswered questions have also surfaced. Drs. Matt Wilson and Patricia Chevez-Barrios discuss those questions and the potential risks of treating the eye first rather than the patient.

Financial Disclosures: Dr. Chevez-Barrios receives grant support from the Children's Oncology Group (NCI). Dr. Wilson has no financial interests to disclose.